Chromocell Therapeutics Corporation (CHRO)

USD 0.59

(-4.76%)

Operating Expenses Summary of Chromocell Therapeutics Corporation

  • Chromocell Therapeutics Corporation's latest annual operating expenses in 2023 was 6.86 Million USD , up 196.02% from previous year.
  • Chromocell Therapeutics Corporation's latest quarterly operating expenses in 2024 Q2 was 1.76 Million USD , down -8.78% from previous quarter.
  • Chromocell Therapeutics Corporation reported a annual operating expenses of 2.31 Million USD in annual operating expenses 2022, up 176.3% from previous year.
  • Chromocell Therapeutics Corporation reported a annual operating expenses of 838.99 Thousand USD in annual operating expenses 2021, down -46.0% from previous year.
  • Chromocell Therapeutics Corporation reported a quarterly operating expenses of 1.93 Million USD for 2024 Q1, down -50.14% from previous quarter.
  • Chromocell Therapeutics Corporation reported a quarterly operating expenses of 1.29 Million USD for 2023 Q3, up 66.21% from previous quarter.

Annual Operating Expenses Chart of Chromocell Therapeutics Corporation (2023 - 2020)

Historical Annual Operating Expenses of Chromocell Therapeutics Corporation (2023 - 2020)

Year Operating Expenses Operating Expenses Growth
2023 6.86 Million USD 196.02%
2022 2.31 Million USD 176.3%
2021 838.99 Thousand USD -46.0%
2020 1.55 Million USD 0.0%

Peer Operating Expenses Comparison of Chromocell Therapeutics Corporation

Name Operating Expenses Operating Expenses Difference
AIM ImmunoTech Inc. 32.07 Million USD 78.606%
Ampio Pharmaceuticals, Inc. 9.26 Million USD 25.957%
Armata Pharmaceuticals, Inc. 11.64 Million USD 41.091%
Actinium Pharmaceuticals, Inc. 52 Million USD 86.804%
Azitra, Inc. 8.3 Million USD 17.346%
Can-Fite BioPharma Ltd. 8.93 Million USD 23.223%
Calidi Biotherapeutics, Inc. 28.99 Million USD 76.33%
CEL-SCI Corporation 31.47 Million USD 78.198%
iBio, Inc. 16.85 Million USD 59.296%
Lineage Cell Therapeutics, Inc. 33 Million USD 79.21%
MAIA Biotechnology, Inc. 20.18 Million USD 65.999%
Matinas BioPharma Holdings, Inc. 24.86 Million USD 72.399%
Navidea Biopharmaceuticals, Inc. 13.93 Million USD 50.743%
NovaBay Pharmaceuticals, Inc. 12.89 Million USD 46.796%
NanoViricides, Inc. 8.51 Million USD 19.42%
Oragenics, Inc. 5.45 Million USD -25.868%
BiomX Inc. 26.81 Million USD 74.408%
BiomX Inc. 26.81 Million USD 74.408%
Protalix BioTherapeutics, Inc. 32.05 Million USD 78.59%
Palatin Technologies, Inc. 34.67 Million USD 80.207%
Scorpius Holdings, Inc. 39.81 Million USD 82.765%